Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Stocks in this Quantisnow insightHealth Care
Historical context for ADIL
Across the 17 sessions after earlier ADIL headlines, the stock closed higher 6 times and lower 11 times, with a median move of 4.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ADIL | SPY |
|---|---|---|---|
| Aug 3, 2026 | Alliance Global Partners initiated coverage on Adial Pharmaceuticals with a new price target | +9.0% | +1.4% |
| Jun 16, 2026 | Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing | -10.9% | -0.6% |
| Jun 11, 2026 | Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing | +38.0% | +1.7% |
| May 11, 2026 | Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update | +0.7% | +0.2% |
| Apr 29, 2026 | Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 | -0.6% | -0.0% |
| Apr 27, 2026 | Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program | -1.3% | +0.2% |
Quantisnow market dataNASDAQ
ADIL
Adial Pharmaceuticals Inc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for ADIL
Full ADIL profile on Quantisnow Follow ADIL and get a push notification the moment its next story breaks.